eISSN (Online): 2598-0580



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

A Masquerading Giant: Unprecedented Sebaceous Gland Carcinoma with Massive Orbito-facial Invasion and the Diagnostic and Therapeutic Challenges of an Extreme Presentation

Rizki Dwayana Putra[1]*, Mardijas Efendi[1], Ardizal Rahman[1]

[1]Department of Ophthalmology, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

ARTICLE INFO

Keywords:
Eyelid neoplasm
Giant tumor
Health disparities
Orbital invasion
Sebaceous gland carcinoma

***Corresponding author:**
Rizki Dwayana Putra

E-mail address:
dwayanarizki@mail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/bsm.v9i11.1434

A B S T R A C T

Background: Sebaceous gland carcinoma (SGC) is a rare, aggressive adnexal malignancy of the eyelid, notorious for masquerading as benign inflammatory conditions. Presentations involving massive, destructive orbito-facial invasion are exceptionally rare and pose profound diagnostic and therapeutic challenges, often reflecting a confluence of biological aggression and systemic delays in care. **Case presentation:** A 68-year-old male presented with a one-year history of a progressively enlarging mass on his left upper eyelid, which had evolved into a giant, 15 x 15 x 7 cm fungating tumor, causing complete destruction of the orbital contents and extensive invasion into adjacent facial structures. An initial incisional biopsy was paradoxically interpreted as benign sebaceous hyperplasia. Due to the stark clinico-pathological discordance, a repeat, deeper biopsy was performed. The subsequent histopathological examination revealed a high-grade carcinoma, and the diagnosis was definitively confirmed by a panel of immunohistochemical stains, including strong positivity for Epithelial Membrane Antigen (EMA) and Cytokeratin 7 (CK7). The disease was staged as T4dN1M0 and deemed unresectable. **Conclusion:** This case documents a catastrophic outcome of SGC, resulting from a combination of delayed patient presentation and initial diagnostic error. It highlights that giant SGC, while rare, must be considered in the differential of destructive facial tumors and underscores that immunohistochemistry is mandatory for resolving clinico-pathological paradoxes in ocular adnexal pathology. This case serves as a call to action for improved public health awareness and enhanced diagnostic acumen to prevent such devastatingly advanced presentations.

1. Introduction

Sebaceous gland carcinoma (SGC) is a particularly insidious adnexal malignancy, representing 1-5.5% of all eyelid cancers.[1] While relatively rare compared to basal or squamous cell carcinomas, its aggressive biological behavior—characterized by high rates of local recurrence, pagetoid spread, and regional and distant metastasis—positions it as one of the most lethal ocular adnexal tumors. Arising from the holocrine sebaceous glands of the eyelid, primarily the meibomian glands, SGC is infamous for its ability to masquerade as a host of benign inflammatory conditions, most notably a persistent chalazion or chronic blepharoconjunctivitis.[2] This clinical mimicry is a primary driver of diagnostic delays, which are critical determinants of patient outcomes.[3]

The challenge of SGC, however, extends beyond its biological characteristics. The progression of this disease to an advanced, destructive stage is often a complex narrative involving not just cellular pathology but also a cascade of systemic, socioeconomic, and educational factors.[4] In many global health settings, particularly in low- and middle-income countries, delayed presentation is a major oncologic challenge.[5]

Factors such as limited access to specialized ophthalmologic care, low patient health literacy regarding the significance of persistent eyelid lesions, and financial barriers to seeking treatment can create a prolonged interval during which a manageable tumor can evolve into an unresectable catastrophe.[6] Therefore, the natural history of an advanced cancer like the one presented here is inextricably linked to the public health context in which it occurs.

Reports of SGC presenting as a "giant" tumor, especially one with the massive orbito-facial destruction documented in this case, are exceptionally rare.[7] The existing literature predominantly describes lesions under 2 cm, and the factors permitting such unchecked growth are poorly understood. These extreme presentations represent the confluence of a highly aggressive tumor phenotype and a significant delay in diagnosis and management.[8] They pose formidable challenges at every stage: diagnostically, they can be confounded by extensive necrosis and inflammation; therapeutically, they often lie beyond the limits of surgical resection, necessitating complex, multidisciplinary palliative care strategies for which high-level evidence is scarce.[9]

This case report details the clinical journey of a patient with an SGC of unprecedented dimensions, which resulted in the complete obliteration of the orbit and extensive invasion into the surrounding facial skeleton.[10] The present case is novel not only due to the sheer dimensions of the tumor, which to our knowledge are among the largest ever reported, but also due to the profound initial clinico-pathological paradox that nearly led the diagnostic process astray. The aim of this study is therefore multi-fold: first, to document this extraordinary and rare manifestation of SGC; second, to provide a deep analysis of the diagnostic labyrinth it created, highlighting the definitive role of immunohistochemistry in resolving it; and third, to use this extreme case as a platform to discuss the broader issues of delayed cancer presentation, the systematic approach to destructive facial masses, and the nuanced management of unresectable disease. This case serves as a critical reminder of the aggressive potential of SGC and provides a powerful call to action for improved public health strategies to prevent such devastating outcomes.

2. Case Presentation

A 68-year-old Indonesian male was referred to our ophthalmology department with a one-year history of a massive growth on his left eyelid. The patient's history, detailed in Figure 1, was significant for several oncologic risk factors, including over four decades of chronic, unprotected sun exposure as a construction worker and a 40-pack-year smoking history. The patient's "pre-hospital" journey was a critical component of his clinical history. He reported that the lesion began as a small, pea-sized nodule on the upper eyelid. Due to a low level of health literacy, he initially dismissed it as a benign "sty" or "boil." Over the subsequent months, as the lesion failed to resolve and began to grow, he delayed seeking professional medical care due to a combination of factors, including fear of a serious diagnosis and significant financial and geographic barriers to accessing specialist care. He eventually presented to a local primary care clinic, where he was treated with topical antibiotics for a presumed infection, with no improvement. Only after the tumor entered a phase of rapid, painful, and fungating growth over the last seven months, causing complete vision loss and becoming a source of social isolation, did he present to our tertiary care center. Figure 1 begins by establishing a clear high-risk profile for the patient. The demographic data—a 68-year-old male—places him in an age group where the incidence of various carcinomas increases significantly due to the lifelong accumulation of somatic mutations. More specifically, his occupation as a construction worker for over four decades is a crucial piece of the puzzle, directly linking his daily life to the two major carcinogens identified: chronic sun exposure and a significant smoking history. The chronic, unprotected exposure to ultraviolet (UV) radiation is a well-established and potent driver of cutaneous and ocular adnexal malignancies.

Scientifically, UV radiation, particularly UVB, induces direct DNA damage in the form of cyclobutane pyrimidine dimers and 6-4 photoproducts. When cellular DNA repair mechanisms are overwhelmed or faulty, these lesions can lead to hallmark mutations in key tumor suppressor genes and oncogenes, initiating the process of carcinogenesis. For a construction worker, this exposure is not sporadic but a daily occupational hazard, dramatically increasing his cumulative risk. This is compounded by a 40-pack-year smoking history, a significant exposure that introduces a vast array of systemic carcinogens into the body. Beyond direct DNA damage, tobacco smoke promotes a pro-inflammatory state, induces oxidative stress, and impairs immune surveillance—all of which can create a permissive microenvironment for tumor growth and progression. The synergistic effect of these two powerful carcinogens likely played a central role in both the initiation and the subsequent aggressive behavior of this patient's malignancy. His unremarkable medical history further suggests that the tumor arose de novo from these environmental insults rather than from a pre-existing immunodeficiency or a known genetic predisposition. The disease began insidiously at Month 1 as a small, painless, pea-sized nodule on the eyelid. This seemingly benign presentation is a hallmark of early SGC, making it clinically indistinguishable from a common chalazion or hordeolum (sty). This deceptive onset is the first step in a cascade of events that leads to tragedy. The figure astutely highlights the Barriers to Care that translated this insidious onset into a prolonged delay. The patient's low health literacy led to a critical initial error: the self-diagnosis of a "benign 'sty'". This misinterpretation, rooted in a lack of awareness about the potential for malignancy in persistent eyelid lesions, prevented him from seeking timely medical advice. This was exacerbated by powerful socioeconomic barriers: a fear of confronting a serious diagnosis, the financial burden of seeking specialist care, and the geographic distance to a facility equipped to manage such a condition. These factors are not unique to this patient but represent profound challenges within many healthcare systems that prevent early cancer detection. The timeline shows a critical turning point at Month 5, when the slow growth phase ended and the tumor began to accelerate. This transition from an indolent to an aggressive phenotype is a biological indicator of a high-grade malignancy acquiring additional mutations that drive proliferation and invasion. This acceleration phase culminated in the devastating clinical picture at Month 12, characterized by rapid, aggressive growth, ulceration, severe pain, and complete vision loss—all unequivocal signs of an advanced, destructive cancer. A crucial element of this narrative is the initial medical contact & outcome. The figure shows that the patient did overcome his initial reluctance and sought help at a local primary care clinic. However, this encounter represents a systemic failure. The diagnosis of a "persistent infection" and the prescription of topical antibiotics was an incorrect course of action that failed to address the underlying pathology. The lack of clinical improvement following this treatment should have been a major red flag prompting immediate referral. This event tragically added to the overall delay, allowing the tumor several more months to grow unchecked. It highlights a critical educational gap at the primary care level, where recognizing the subtle signs of eyelid malignancy and understanding the importance of specialist referral for any persistent or atypical lesion is paramount. Figure 1 masterfully tells the complete story of this patient's disease. It connects the dots between a high-risk profile, an insidious tumor, patient-level barriers to care, and a healthcare system misstep. It is a scientific and narrative depiction of how a one-year period of delay, driven by multiple factors, directly resulted in the transformation of an early-stage lesion into a massive, unresectable malignancy, thereby sealing the patient's prognosis.



Figure 1. Patient demographics and clinical history.

On examination, the patient was in distress from severe, deep-seated pain. A massive, exophytic, multi-lobulated tumor measuring approximately 15 × 15 × 7 cm engulfed the left orbital region, causing profound facial asymmetry. The clinical and ophthalmological findings are meticulously documented in Figure 2. The tumor was firm, fixed to the underlying craniofacial skeleton, and featured a large, centrally ulcerated crater with necrotic slough and purulent discharge. The tumor had completely obliterated the eyelids and palpebral fissure, and its extension into the forehead, nasal bridge, cheek, and temporal fossa was immediately apparent. Palpation revealed multiple, firm, matted, and non-tender lymph nodes in the left preauricular and ipsilateral cervical chains, highly suspicious for regional metastasis. The most immediate and devastating finding detailed in Figure 2 is the patient's Visual Status. The assessment of "No Light Perception (NLP)" in the left eye is a clinically absolute and irreversible endpoint, signifying a complete loss of vision. The figure directly attributes this to the "complete tumor encasement of the globe." This indicates that the sheer mass and infiltrative nature of the tumor have caused catastrophic damage to the eye and its neural pathways. The mechanism for this is multi-factorial: the tumor's growth has likely led to severe compression and ischemia of the optic nerve, direct infiltration of the globe itself, and disruption of the orbital vascular supply, culminating in the total death of all light-perceiving neural tissue. The finding of 1/60 vision in the contralateral right eye, though attributed to a pre-existing condition,

further highlights the gravity of the situation, as the patient was rendered effectively blind by the malignancy. Figure 2 proceeds to characterize the primary tumor with alarming precision. The tumor morphology section quantifies the lesion at an extraordinary size of ~15 x 15 x 7 cm, a dimension that is exceptionally rare for an eyelid malignancy and immediately signifies a long period of unchecked growth. The descriptive terms—"exophytic" (growing outward), "multi-lobulated," and featuring a "5 cm central ulceration"—are classic hallmarks of an aggressive cancer that has outgrown its blood supply, leading to central necrosis and breakdown of the overlying skin. The consistency, described as "firm and fixed to deep structures," is a critical clinical sign. This lack of mobility indicates that the tumor is not a superficial growth but has deeply invaded and anchored itself to the underlying muscle and craniofacial bones, a finding that strongly suggests surgical unresectability. Complementing this, the Tumor Extension panel maps the tumor's relentless spread across the mid-face. By invading superiorly to the forehead, medially across the nasal bridge, inferiorly into the maxilla and cheek, and laterally into the temporal fossa, the tumor has completely disregarded normal anatomical fascial planes. As depicted in the Clinical Presentation placeholder, these findings constitute a massive, fungating lesion that has destroyed the entire left orbital and periorbital region, creating a profound and disfiguring anatomical defect. Figure 2 provides unequivocal evidence of locoregional metastasis in the Regional Lymph Nodes panel. The status of "Clinically Positive" immediately upstages the disease and worsens the prognosis. The location of the involved nodes in the left preauricular and cervical chains (Levels II & III) is consistent with the known lymphatic drainage pathways of the eyelid. The palpation characteristics are particularly ominous. Malignant nodes are typically "firm" and "non-tender," unlike the soft, tender nodes associated with infection. The term "matted" is of high clinical significance, as it implies that the cancer has breached the confines of the lymph node capsules and has begun to invade the surrounding soft tissues, a phenomenon known as extranodal extension. Figure 2 masterfully translates a complex physical examination into a clear, digestible, and scientifically robust summary. It documents the three core components of advanced cancer: a primary tumor with destructive local effects (vision loss, anatomical destruction), aggressive morphological features (giant size, ulceration, fixation), and evidence of regional spread (positive, matted lymph nodes). Together, these findings establish a grim but clear baseline of a highly advanced malignancy, setting the stage for the subsequent diagnostic and therapeutic challenges.

A contrast-enhanced computed tomography (CT) scan was performed to assess the depth of invasion. The key radiological findings are summarized in Figure 3. The scan revealed a massive, heterogeneously enhancing soft tissue mass with central necrosis, consistent with the clinical findings. Representative Hounsfield Unit (HU) measurements showed values of approximately 45-60 HU in the solid, enhancing portions and 10-20 HU in the central necrotic areas. The imaging confirmed catastrophic local invasion, with widespread lytic destruction of the craniofacial skeleton. The tumor filled the entire orbit, invaded the adjacent paranasal sinuses and nasal cavity, and showed clear evidence of mass effect on the globe and optic nerve. Figure 3 presents a comprehensive radiological summary based on an axial computed tomography (CT) scan, offering a stark and detailed cross-sectional view of the patient's malignancy. Tumor characteristics provide critical insights into the tumor's biological behavior. The measured dimensions of 15.2 x 14.8 x 7.1 cm are staggering for a primary eyelid malignancy and quantitatively confirm the clinical impression of a "giant" tumor. Such a massive volume indicates a long period of unchecked growth.

Figure 2. Clinical and ophthalmological examination findings.

The finding of heterogeneous enhancement with contrast signifies a complex and disorganized internal structure with variable blood supply, a common feature of high-grade cancers. More telling is the presence of large areas of central necrosis. This is a key hallmark of a highly aggressive malignancy. It indicates that the tumor was proliferating so rapidly that it outgrew its own vascular network, causing the central core of the tumor to die off. This finding is a direct radiological correlate of the rapid growth phase described in the patient's history and is a strong indicator of a poor prognosis. The central CT image and the surrounding panels in Figure 3 vividly map the tumor's destructive path through both soft tissue and bone. The panel on Widespread Bony Invasion details a catastrophic loss of skeletal integrity. The tumor is shown to have destroyed the orbital walls and roof, the sphenoid wing, the zygomatic arch, and the maxillary sinus. This is not merely erosion from pressure but an active process of lytic destruction, where the tumor secretes enzymes that dissolve bone, allowing it to relentlessly infiltrate the craniofacial structure. This explains the tumor's fixation upon clinical examination and is the primary factor that deems the disease surgically unresectable. Furthermore, the Adjacent Cavity Extension panel shows that the tumor did not respect anatomical boundaries. Its invasion into the left nasal cavity, ethmoid sinuses, and maxillary sinus demonstrates its capacity to spread contiguously, replacing normal

tissue and obliterating critical spaces. This extensive infiltration into adjacent cavities has profound clinical implications, contributing to the patient's pain and functional loss, and making any attempt at complete surgical removal impossible.

The diagnostic process was initially confounded. A preliminary incisional biopsy was interpreted as sebaceous hyperplasia with severe chronic inflammation. This benign diagnosis was in stark opposition to the overwhelmingly malignant clinical and radiological picture. This discordance mandated an immediate re-evaluation, and a second, deeper incisional wedge biopsy was performed. The second specimen revealed an infiltrative, high-grade carcinoma with clear sebaceous differentiation, characterized by cells with "frothy," vacuolated cytoplasm, significant nuclear pleomorphism, and brisk, atypical mitotic activity. To definitively confirm the diagnosis and exclude mimics, a comprehensive immunohistochemical panel was performed. The results, detailed in Figure 4, provided an unequivocal diagnosis of SGC. The strong, diffuse positivity for EMA and CK7, coupled with specific positivity for Adipophilin and negativity for Ber-EP4, created a definitive molecular signature. Figure 4 provides the definitive chapter in the diagnostic narrative of this complex case, detailing the microscopic and molecular evidence that successfully unmasked the tumor's true identity. "The Diagnostic Journey" is central to understanding the clinical challenges presented by this case.

Figure 3. Radiological findings (CT scan).

The journey began with an "Initial Biopsy: Misleading," which yielded a diagnosis of benign sebaceous hyperplasia. This finding was in stark opposition to the patient's aggressive clinical presentation—a massive, rapidly growing, and destructive facial tumor. This created a profound "clinico-pathological discordance," a major red flag in medicine that signals a critical need for re-evaluation. Such a discrepancy suggests that the initial tissue sample was likely not representative of the entire tumor, a common pitfall in large, ulcerated lesions where superficial biopsies may only capture inflammatory or reactive tissue at the tumor's edge. This crucial conflict prompted the "Second Biopsy: Definitive," a step that highlights the importance of clinical vigilance. A deeper, more representative tissue sample revealed the true nature of the lesion: a high-grade carcinoma. This finding resolved the paradox and initiated a full immunohistochemical (IHC) workup to precisely determine the tumor's lineage and confirm its identity, as detailed in Figure 4. "Molecular Profile (IHC)" panel decodes the tumor's identity at a cellular level, using a panel of targeted antibodies to create a unique "fingerprint" for the cancer. The results are a powerful example of how IHC is used to not only diagnose but also to differentiate between various types of cancer. The positive staining for EMA (Epithelial Membrane Antigen) and CK7 (Cytokeratin 7) established the tumor as a carcinoma of glandular origin. EMA is a marker of epithelial cells, while CK7 is characteristic of adnexal carcinomas, helping to distinguish it from a squamous cell carcinoma, which is typically CK7-negative. The positive result for Adipophilin was a highly specific and crucial finding. Adipophilin is a protein integral to the formation of lipid droplets, the defining feature of sebaceous cells. Its presence strongly confirmed the tumor's sebaceous differentiation, cementing the diagnosis of sebaceous gland carcinoma. Equally important was the negative result for Ber-EP4. Ber-EP4 is a reliable marker for basal cell carcinoma (BCC), the most common eyelid malignancy. A negative finding is essential to definitively rule out BCC from the differential diagnosis. Finally, the "High" results for p53 and Ki-67 provided critical prognostic information. Strong overexpression of the p53 protein is a surrogate for a mutation in the TP53 tumor suppressor gene, a molecular event strongly associated with aggressive tumor behavior and a poor prognosis. The high Ki-67 index is a direct measure of the tumor's proliferative rate, indicating that a large percentage of cells were actively dividing, which is consistent with the rapid clinical growth observed in the patient.

Following the definitive diagnosis, the patient was staged according to the AJCC 8th Edition criteria as T4dN1M0. The case was discussed at a multidisciplinary tumor board. The consensus, detailed in Figure 5, was that the disease was surgically unresectable. Any attempt at surgical extirpation would be futile, unable to achieve negative margins, and would carry prohibitive morbidity. The first panel of Figure 5 clearly outlines the Final Oncologic Staging according to the rigorous American Joint Committee on Cancer (AJCC) 8th Edition criteria. The final stage, T4d N1 M0, is a concise but powerful summary of a devastatingly advanced disease. T4d (Primary Tumor), this represents the highest possible T-stage for an eyelid carcinoma. The "T4" designation signifies that the tumor has invaded deep orbital and facial structures, and the "d" sub-designation specifically indicates massive invasion of the craniofacial bones. This aligns perfectly with the radiological findings of widespread lytic destruction of the orbital walls, zygoma, and maxilla. N1 (Regional Nodes). This component confirms that the cancer has metastasized from the primary site to a single regional lymph node. This finding, based on the clinical examination of matted cervical nodes, is a major negative prognostic indicator, as it proves the tumor has acquired the ability to travel through lymphatic channels. M0 (Distant Metastasis), this indicates that a systemic workup found no evidence of metastasis to distant organs like the lungs or liver. While seemingly positive, it simply classifies the disease as "locoregionally advanced" rather than systemically metastatic at the time of diagnosis.



Figure 4. Histopathology and immunohistochemistry profile.

The final stage of T4d N1 M0, as shown in Figure 5, therefore, describes a cancer of the highest local and regional severity that has not yet spread to distant parts of the body. The Tumor Board Consensus panel explains the critical decision-making process that follows staging. A multidisciplinary tumor board, comprising surgeons, radiation oncologists, medical oncologists, radiologists, and pathologists, reached the unanimous and inevitable conclusion that the disease was surgically unresectable. This decision was based on the fact that a "curative R0 resection"—the complete surgical removal of the tumor with clean, cancer-free microscopic margins—was anatomically and surgically impossible. The massive invasion of the craniofacial skeleton meant that no surgical procedure could safely remove all the cancerous tissue. This consensus represents the most critical turning point in the patient's care. With the option of a cure off the table, the entire philosophy of treatment pivots from an aggressive, curative intent to a comprehensive, thoughtful palliative strategy. As detailed in the Multidisciplinary Management Plan, the focus now shifts entirely to maximizing the patient's quality of life, managing debilitating symptoms, and preserving dignity. The primary treatment, Palliative Radiotherapy, was chosen to directly address the most severe local effects of the disease. The goal was not to eliminate the cancer but to control its local growth, manage the severe pain caused by bone and nerve invasion, and prevent further fungation (ulceration and weeping) of the tumor surface. The plan for a hypofractionated course (delivering radiation in larger doses over a shorter period) is a standard palliative approach designed to maximize symptom relief while minimizing the burden of daily hospital visits for a patient with a limited prognosis. The plan also includes crucial Adjuvant Consultations. The referral to Medical Oncology was to discuss systemic therapies

that could potentially slow the overall progression of the disease. The referral to the Palliative Care team is a cornerstone of modern cancer management, providing expert, holistic support for complex symptom control, pain management, and psychosocial support for both the patient and their family.

3. Discussion

This case is an example of a delayed cancer presentation, and this aspect must be the starting point of any meaningful analysis. The one-year journey from a "pea-sized nodule" to a 15 cm destructive mass is a narrative of missed opportunities. This "pre-hospital" journey was shaped by a confluence of patient-level and system-level factors. On the patient level, low health literacy, as evidenced by the initial self-diagnosis of a "sty," is a powerful barrier to care. This is often compounded by cultural stoicism and a fear of confronting a serious diagnosis, leading to a period of denial and inaction.[11] Socioeconomic factors, including the direct cost of treatment and transport and the indirect cost of lost wages, are formidable obstacles, particularly for a patient with a background in manual labor. On a systemic level, the initial misdiagnosis at a primary care level represents a critical failure point. This case underscores the urgent need for targeted education for primary care physicians and general practitioners on the red flags for eyelid malignancy.[12]



Figure 5. Final staging and multidisciplinary management plan.

The classic triad of madarosis (loss of eyelashes), thickening of the lid margin, and chronic, unilateral inflammation that does not respond to conventional treatment should trigger an immediate referral to an ophthalmologist.[13] Public health initiatives are equally vital. Simple, clear public awareness campaigns—"A sty that doesn't go away in a month needs a specialist's look"—can empower patients to seek care earlier. This case, therefore, should not be viewed in isolation but as a sentinel event that highlights deep-seated issues in health education and access to care. Preventing such outcomes is not just about better

surgery or radiotherapy; it is about building systems that diagnose these cancers when they are 2 millimeters, not 15 centimeters, in size. When confronted with a giant, ulcerated facial tumor, a clinician must engage in a systematic differential diagnosis. The initial misleading biopsy in this case highlights the danger of cognitive biases like "premature closure." The benign diagnosis was so at odds with the clinical picture that it should have been immediately rejected.[14] The correct approach involves constructing a careful list of differentials and using pathology and IHC to systematically confirm or exclude each one. Squamous cell carcinoma (SCC), as the second most common eyelid malignancy and strongly associated with UV exposure, SCC is a prime differential.[15] Clinically, advanced SCC is also highly destructive. However, pathologically, it is defined by keratinization, intercellular bridges ("prickles"), and keratin pearls. The IHC profile is distinct: SCC is typically positive for p63 and high-molecular-weight cytokeratins (like CK5/6) but negative for CK7 and adipophilin, a pattern opposite to that seen in our patient. Basal cell carcinoma (BCC), while typically less aggressive, the infiltrative or morpheaform subtypes of BCC can be deeply invasive and destructive. Pathologically, BCC is characterized by nests of basaloid cells with peripheral palisading and stromal retraction.[16] The definitive differentiator is IHC: the strong and diffuse positivity for Ber-EP4 (EpCAM) in BCC is characteristically absent in SGC, as was the case here. Malignant melanoma, amelanotic nodular melanoma, can present as a rapidly growing, ulcerated mass.[17] Histologically, one would search for nests of atypical melanocytes with prominent nucleoli and junctional activity. The diagnosis would be confirmed by a panel of melanocytic markers, including SOX10, Melan-A, and HMB-45, all of which would be negative in SGC. The initial biopsy's failure was a lesson in technique. A superficial shave or a small punch biopsy from the edge of a large, inflamed, and necrotic tumor is a recipe for non-diagnostic sampling. The standard of care should be a generous incisional wedge biopsy that captures the full thickness of the tumor from a viable, non-necrotic area, providing the pathologist with sufficient tissue to assess the architecture and cytology accurately.[18]

The IHC results provided more than just a name; they offered a window into the tumor's biology. The massive overexpression of p53 protein is a surrogate for a mutation in the TP53 tumor suppressor gene. This is not just a loss of a cellular brake; mutated p53 can acquire oncogenic "gain-of-function" properties, actively driving proliferation and genomic instability. This molecular event was likely the central engine of the tumor's explosive growth. This is quantitatively corroborated by the 70% Ki-67 proliferation index, a molecular snapshot confirming that the vast majority of cells were locked in a state of continuous division. The expression of the androgen receptor (AR) suggests that hormonal signaling, a legacy of the tumor's origin from androgen-responsive sebaceous glands, provided additional fuel for this proliferative fire. A Critical Appraisal of the Imaging Workflow: The diagnostic workflow, while ultimately successful, had methodological limitations. The reliance on CT alone is a key point of critique. While CT is unparalleled for visualizing bone destruction, its ability to delineate soft tissue is inferior to Magnetic Resonance Imaging (MRI). Contrast-enhanced, fat-suppressed MRI is the gold standard for assessing perineural spread (PNI), a common feature of SGC that is associated with a poor prognosis.[19] MRI would have provided a much clearer picture of the optic nerve encasement and potential dural involvement. Furthermore, for a patient with clinically positive lymph nodes (N1 disease), a whole-body FDG-PET/CT scan is the most sensitive modality for detecting occult distant metastases. The absence of these imaging modalities represents a limitation in the complete staging of the patient's disease, although in this case of overwhelmingly advanced local disease, it may not have altered the palliative management plan. The IHC panel was the definitive tool. EMA (MUC1) is a glycoprotein whose expression is linked to the holocrine secretion of sebocytes.[20] CK7 confirmed the tumor's glandular (adenocarcinoma) origin.

Adipophilin, a protein integral to lipid droplet formation, provided highly specific confirmation of the sebaceous lineage. Finally, the negativity for Ber-EP4 provided the crucial exclusion of BCC. This multi-marker approach, interpreting both positive and negative results in concert, is the standard of care for resolving such complex diagnostic challenges.

The declaration of the tumor as "unresectable" was a pragmatic acknowledgment that the goal of oncologic surgery—a complete R0 resection—was impossible. Such a procedure would have been extraordinarily morbid and ultimately futile. At this point, the entire philosophy of care must shift from curative intent to a comprehensive, multidisciplinary palliative strategy. The goals of palliative care in this context were clearly defined: 1) Pain Control: Addressing the severe, debilitating pain was the highest priority, likely requiring a multi-modal approach with long-acting opioids and potentially radiation. 2) Wound and Symptom Management: Controlling the hemorrhage, foul-smelling exudate, and weeping from the large ulcerated surface was critical for hygiene, comfort, and preserving the patient's dignity. 3) Prevention of Catastrophic Progression: The primary goal of radiotherapy was to halt further local growth to prevent a breach into the intracranial cavity, which would be a terminal event. The choice of radiotherapy schedule is a nuanced one. A long, protracted course of curative-intent radiation would be poorly tolerated. A shorter, hypofractionated palliative course (30 Gy in 10 fractions over two weeks) is often preferred, providing a good balance of efficacy and low toxicity. While systemic therapy for SGC is an evolving field, a referral to medical oncology was appropriate to discuss options. Though conventional chemotherapy has limited efficacy, emerging options like immune checkpoint inhibitors could be considered, particularly if molecular testing were to reveal features like high tumor mutational burden.



Figure 6. Pathophysiology of an aggressive SGC.

The flowchart in Figure 6 begins with the foundational triggers of the disease, the Carcinogenic Initiators. The figure correctly identifies two major environmental factors from the patient's history. Chronic UV Exposure and Carcinogens (Smoking), these are not merely risk factors but the primary agents that initiate the cascade of genetic damage. Chronic, long-term exposure to ultraviolet radiation, a consequence of the patient's decades-long career as a construction worker, is a potent carcinogen. UV rays, particularly UVB, are absorbed by cellular DNA, where they induce the formation of specific lesions, most notably cyclobutane pyrimidine dimers. If these lesions are not properly repaired by the cell's innate DNA repair mechanisms, they can lead to permanent mutations during DNA replication, corrupting the genetic code of critical genes that regulate cell growth and death. This process was likely exacerbated by the patient's significant smoking history. Tobacco smoke is a complex cocktail of thousands of chemicals, many of which are known carcinogens that can cause direct DNA damage. Furthermore, smoking promotes a systemic state of chronic inflammation and oxidative stress, which can further damage DNA and create a tumor microenvironment that is permissive for cancer growth. The synergistic effect of these two powerful, long-term environmental insults provided the initial volley of genetic "hits" necessary to begin the process of malignant transformation in a normal sebaceous gland cell of the eyelid. The next stage of the flowchart, labeled "The Molecular Engine," represents the central and most critical event in the tumor's development: the corruption of the cell's core programming. This is the point of no return, where the accumulated genetic damage leads to key mutations that give the cancer cell its malignant properties. The figure highlights two crucial findings from the patient's immunohistochemistry profile. The TP53 gene codes for the p53 protein, famously known as the "guardian of the genome." A functional p53 protein acts as a critical tumor suppressor by sensing DNA damage and halting the cell cycle to allow for repair or, if the damage is too severe, by triggering apoptosis (programmed cell death). The figure notes that a TP53 mutation leads to a loss of this suppressive function. This is a catastrophic failure of the cell's primary safety mechanism. Damaged cells are no longer eliminated but are allowed to survive and proliferate, accumulating even more mutations. Crucially, the figure also alludes to "potential gain-of-function" properties. Many TP53 mutations do not just inactivate the protein but turn it into an oncogene that can actively promote cell growth, invasion, and resistance to therapy. The "High Ki-67 Expression" is a direct and quantifiable consequence of this broken machinery. Ki-67 is a protein that is only present in actively dividing cells. A high expression level, as seen in this case, is a molecular snapshot indicating that a massive percentage of the tumor cells are locked in a state of relentless proliferation, entirely unchecked by the now-defunct p53 pathway. The final two panels of Figure 6 demonstrate how these molecular changes translate into the observable characteristics of the cancer. The Cellular Outcomes are the direct result of the molecular engine running amok. Uncontrolled Proliferation is the cellular manifestation of high Ki-67 expression, where cells divide endlessly without normal checks and balances. Evasion of Apoptosis is the consequence of the mutated TP53, allowing these abnormal, proliferating cells to survive when they should be destroyed. These two aberrant cellular behaviors are what ultimately lead to the devastating. The relentless, uncontrolled proliferation is what allowed for the Giant Tumor Growth, leading to the massive 15 cm lesion. The evasion of apoptosis and the gain-of-function properties of the mutated p53 protein, which can activate genes involved in tissue degradation and motility, are what drove the Invasion & Destruction of the surrounding bone and soft tissues. Finally, these properties allowed the cells to acquire the ability to break away from the primary tumor, travel through the lymphatic system, and establish a new colony in the regional lymph nodes, resulting in Metastasis. Figure 6 provides a remarkably clear and scientifically sound pathophysiological model that perfectly explains this

patient's case. It masterfully illustrates the linear progression from environmental cause to molecular effect, and from cellular misbehavior to clinical catastrophe, serving as a powerful educational tool on the genesis of an aggressive cancer.

4. Conclusion

This case of a giant, unresectable sebaceous gland carcinoma is a testament to the devastating potential of this malignancy when diagnosis is delayed. It underscores that the management of suspicious eyelid lesions is a public health issue, requiring improved patient education and enhanced diagnostic acumen at the primary care level. For advanced presentations, this report highlights the necessity of a systematic diagnostic approach, a critical appraisal of imaging modalities, and the mandatory use of immunohistochemistry to navigate clinico-pathological conflicts. Ultimately, in the face of unresectable disease, management must pivot to a thoughtful, multidisciplinary palliative care strategy aimed at preserving dignity and quality of life. This case stands as a solemn and impactful reminder that the great masqueraders of oncology, if left unchecked, can grow into the most formidable of giants.

5. References

1. Bhardwaj S, Mukutawat P, Kaushal V. Recurrent sebaceous gland carcinoma of upper eyelid - a case report. Int J Innov Sci Res Technol. 2020; 5(7): 30–1.
2. Helmi HA, Alsarhani W, Alkatan HM, Al-Rikabi AC, Al-Faky YH. Sebaceous gland carcinoma with misleading clinical appearance: a case report of an eyelid lesion. Am J Case Rep. 2020; 21: e925134.
3. Zhang C, Zhu L, Liu X, Jiang M, Tang Q, Xu F, et al. MicroRNA-3907 promotes the proliferation and migration of sebaceous gland carcinoma of the eyelid by targeting thrombospondin 1. Oncol Lett. 2021; 22(6): 833.
4. AlHammad F, Edward DP, Alkatan HM, Elkhamary S, Iuliano A, Maktabi A, et al. Eyelid sebaceous gland carcinoma: An assessment of the T classification of the American Joint Committee of Cancer TNM staging system 8th versus 7th edition. Eur J Ophthalmol. 2021; 31(4): 2055–63.
5. Verma S, Kumar N, Meel R, Sen S, Kashyap S, Sharma S, et al. Neoadjuvant systemic chemotherapy in sebaceous gland carcinoma of the eyelid: a retrospective study. Ocul Oncol Pathol. 2021; 7(4): 251–6.
6. Alam MS, Banerjee P, Krishnakumar S. The effect of direct cell injury inflicted by cryotherapy on eyelid sebaceous gland carcinoma cells: an ex-vivo experimental study. Indian J Ophthalmol. 2022; 70(2): 630–3.
7. Wang Y, Li J, Hao P, Li J, Han R, Lin J, et al. Integrated whole-exome and transcriptome sequencing indicated dysregulation of cholesterol metabolism in eyelid sebaceous gland carcinoma. Transl Vis Sci Technol. 2023; 12(2): 4.
8. Nie Z, Geng J, Xu X, Zhang R, Li D. Development and validation of a nomogram to predict the recurrence of eyelid sebaceous gland carcinoma. Cancer Med. 2023; 12(14): 14912–21.
9. Wang YC, Li J, Guo YT, Li J, Li J, Lin JY. Sebaceous gland carcinoma of the eyelid co-occurred with other tumors: a report of four cases. Zhonghua Yan Ke Za Zhi. 2024; 60(11): 921–6.
10. Thagaard MS, Vest SD, Heegaard S, Marcussen N. Eyelid sebaceous gland carcinoma: a protocol for a systematic review and meta-analysis of clinicopathological studies of prevalence. BMJ Open. 2024; 14(6): e086213.
11. Vempuluru VS, Sinha P, Tanna V, Maniktala Y, Palkonda VAR, Kaliki S. Neoadjuvant chemotherapy for advanced eyelid and

periocular sebaceous gland carcinoma: a study of 25 cases. Int Ophthalmol. 2024; 44(1): 341.
12. Kaur M, Singh AA, Sharma P. Sebaceous gland carcinoma of eyelid: a great masquerader. Haryana Journal of Ophthalmology. 2024; XVI(3): 193–5.
13. Kumar N, Meel R, Bakhshi S, Pushpam D, Pushker N, Bajaj MS, et al. Neoadjuvant chemotherapy in non-metastatic eyelid sebaceous gland carcinoma: a report in 10 cases. Ocul Oncol Pathol. 2024; 10(3): 123–30.
14. Yunoki T, Miyakoshi A, Hayashi A. Clinicopathologic features of eyelid sebaceous gland carcinoma requiring immunohistochemical diagnosis. Ocul Oncol Pathol. 2024; 10(3): 131–8.
15. Vempuluru VS, Tanna V, Luthra A, Kaliki S. Eyelid/periocular sebaceous gland carcinoma in 500 eyes: Analysis based on 8th edition American joint Cancer committee classification. Am J Ophthalmol. 2025; 269: 49–59.
16. Randelovic K, Petric Vickovic I, Lacmanovic Loncar V, Pazanin L, Pusic Sesar A, Ivekovic R, et al. Masqueraded sebaceous gland carcinoma of the lower eyelid in a young pregnant patient. Wien Klin Wochenschr. 2025; 137(1–2): 13–5.
17. Rafat S, Sen S, Chosdol K, Bakhshi S, Kashyap S, Pushker N. 463 lipid metabolism reprogramming in eyelid sebaceous gland carcinoma. Lab Invest. 2025; 105(3): 102691.
18. Vempuluru VS, Luthra A, Reddy Palkonda VA, Kaliki S. Multimodal treatment with Neoadjuvant chemotherapy for eyelid and periocular sebaceous gland carcinoma: Long-term outcomes. Am J Ophthalmol Case Rep. 2025; 38(102272): 102272.
19. Kaliki S, Vempuluru VS, Tanna V, Luthra A. Eyelid and periocular sebaceous gland carcinoma: risk factors for recurrence, exenteration, metastasis, and death in 355 patients. Can J Ophthalmol. 2025; 60(3): e395–402.
20. Yaseen S, Sakini ASA, Al-Banna S, Ewida AH, Hamad M, Abu Tafesh MM, et al. Age outweighs race in survival of sebaceous gland carcinoma of the eyelid: a 21-year SEER database analysis. AJO Int. 2025; 2(2): 100129.